PureTech Health
PRTC
PRTC was delisted on the 20th of May, 2026.
3 hedge funds and large institutions have $2.4M invested in PureTech Health in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
5% more capital invested
Capital invested by funds: $2.29M → $2.4M (+$105K)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| 1 |
Jane Street
New York
|
+$13.8K |
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$28 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $2.12M | – | – | – |
|
|
2
Jane Street
New York
| $280K | +$13.8K | +499 | +5% |
|
|
3
UBS Group
Zurich,
Switzerland
| $570 | -$28 | -1 | -5% |
|
PRTC Hedge Fund Activity: Q2 2023 in Review
3 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in PureTech Health (PRTC) for Q2 2023, worth a combined $2.4M — up 4.6% from $2.29M a quarter earlier.
Fund positioning in PRTC was balanced in Q2 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Jane Street, adding an estimated $13.8K. The largest seller was UBS Group, cutting an estimated $28.
- 3 institutional investors held PureTech Health (PRTC) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $2.4M of PureTech Health stock for Q2 2023, up 4.6% quarter-over-quarter.
- 0 funds opened new PureTech Health positions in Q2 2023 and 0 closed out.
- The largest PureTech Health buyer in Q2 2023 was Jane Street, an estimated $13.8K added.
- The largest PureTech Health seller in Q2 2023 was UBS Group, an estimated $28 sold.
Based on aggregated 13F filings for Q2 2023.